Kala Pharmaceuticals has completed enrollment in the STRIDE 3 trial for KPI-121 0.25%, a treatment for temporary dry eye relief, according to a press release.
The enrollment follows a previous new drug application rejection from the FDA, which said that efficacy data from an additional clinical trial would be needed to support the resubmission of KPI-121 0.25%. The drug, branded Eysuvis, uses Kala’s Ampplify mucus-penetrating particle drug delivery technology to enhance penetration of loteprednol etabonate into the eye.
The phase 3 multicenter, randomized, double-masked,
Uncategorized